Abstracts tagged "medication side effects"

Abstract Number: 2476 • 2019 ACR/ARP Annual Meeting
Side Effects of Methotrexate and TNFi: Differences in Tolerability Among Patients with PsA and RA
Alexis Ogdie¹, Ervant Maksabedian ², Bradley Stolshek ², Yomei Shaw ³ and Kaleb Michaud ⁴, ¹University of Pennsylvania, Philadelphia, PA, ²Amgen Inc., Thousand Oaks, CA, ³FORWARD, The National Databank for Rheumatic Diseases, Wichita, KS, ⁴FORWARD, The National Databank for Rheumatic Diseases and University of Nebraska Medical Center, Wichita, KS
Background/Purpose: Methotrexate (MTX) is generally well tolerated in rheumatoid arthritis (RA) but little is known about the tolerability of MTX in psoriatic arthritis (PsA). One…
Abstract Number: 1983 • 2016 ACR/ARHP Annual Meeting
Pain and Sensitization in Women with Aromatase Inhibitor-Associated Arthralgias
Monica Crespo-Bosque¹, Carrie Brown², Brenda Cartmel³, Maura Harrigan⁴, Melinda Irwin³ and Tuhina Neogi⁵, ¹Internal Medicine, Boston Medical Center, Boston, MA, ²Boston University School of Public Health, Boston, MA, ³Yale School of Public Health, New Haven, CT, ⁴Cancer Center, Yale School of Public Health, New Haven, CT, ⁵Clinical Epidemiology, Boston University School of Medicine, Boston, MA
Background/Purpose: Aromatase inhibitors (AIs) are the preferred treatment for estrogen receptor positive breast cancer in postmenopausal women, but are frequently associated with arthralgias, which can…
Abstract Number: 3142 • 2016 ACR/ARHP Annual Meeting
Improving Counseling, Documentation and Adherence to Highly Effective Birth Control in Women on Teratogenic Medications at a Rural Medical Center: A Quality Improvement Initiative
Sonal Bhalla^1,2,3, John Mecchella^1,4 and Alicia Zbehlik^1,4,5, ¹Rheumatology, Dartmouth-Hitchcock Medical Center, Lebanon, NH, ²Rheumatology/ Leardership Peventive Medicine Residency, Dartmouth-Hitchcock Medical Center, Lebanon, NH, ³Instructor in Medicine, Geisel School of Medicine at Dartmouth, Hanover, NH, ⁴Geisel School of Medicine at Dartmouth, Hanover, NH, ⁵Leadership Preventive Medicine/Rheumatology, Dartmouth-Hitchcock Medical Center, Lebanon, NH
Background/Purpose: Autoimmune and inflammatory diseases occur more often in women than in men, and often these women are of childbearing age. Many of the medications…
Abstract Number: 2436 • 2015 ACR/ARHP Annual Meeting
Views and Prescribing Habits of Pneumocystis Prophylaxis in the Pediatric Rheumatology Community
Matthew Basiaga¹, Alexis Ogdie-Beatty² and for the CARRA Investigators, ¹Pediatric Rheumatology, The Children's Hospital of Philadelphia, Philadelphia, PA, ²Medicine/Rheumatology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Pneumocystis pneumonia (PCP) is a potentially devastating opportunistic infection. The incidence of PCP and the risk of adverse events secondary to prophylactic medication in…
Abstract Number: 2505 • 2015 ACR/ARHP Annual Meeting
A Fellow Led Quality Improvement Project for Improving Contraceptive Compliance in Women Receiving Teratogenic Medications
Melissa Wells¹, Victoria Lackey², Erica Peart³, Nicholas Holdgate⁴, Samya Mohammad¹, Stephen Balevic¹, Rebecca Sadun⁴, Lisa G. Criscione-Schreiber⁵, Megan E. B. Clowse³ and Mamata Yanamadala⁶, ¹Division of Rheumatology, Department of Medicine, Duke University, Durham, NC, ²Dept of Medicine, Division of Rheumatology, Duke University, Durham, NC, ³Rheumatology, Duke University, Durham, NC, ⁴Rheumatology, Duke University Medical Center, Durham, NC, ⁵Dept of Med/Rheum Div, Duke University, Durham, NC, ⁶Division of Geriatrics, Department of Medicine, Duke University, Durham, NC
Background/Purpose: Women of child bearing age with autoimmune diseases are often prescribed teratogenic medications. Contraceptive compliance in this group of patients has been shown to…
Abstract Number: 1360 • 2014 ACR/ARHP Annual Meeting
Monitoring Methotrexate and Leflunomide Treatment for Liver Toxicity: the Kaiser Permanente Experience
Robert Goldfien¹ and Lisa Herrinton², ¹Rheumatology, Kaiser Permanente, Richmond, CA, ²Division of Research, Kaiser Permanente, Oakland, CA
Background/Purpose: Methotrexate (MTX) and Leflunomide (LEF) are widely prescribed to treat rheumatologic and other diseases. Each has the potential to cause liver injury in some…
Abstract Number: 1853 • 2012 ACR/ARHP Annual Meeting
Rheumatoid Arthritis Patients’ Experiences of Medication Side Effects and Subsequent Decision Making about Medications
Yomei Shaw¹, Ilinca D. Metes², Susan L. Zickmund³, Dawn McBride², Kelly A. Reckley², Stephen R. Wisniewski⁴, Larry W. Moreland², Mark S. Roberts¹ and Marc C. Levesque², ¹Department of Health Policy and Management, University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA, ²Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, ³Division of General Internal Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, ⁴Epidemiology, University of Pittsburgh, Graduate School of Public Health, Pittsburgh, PA
Background/Purpose: Medication adherence in rheumatoid arthritis (RA) patients can be influenced by their previous experiences with medication side effects. Negative experiences may lead patients to…
Abstract Number: 298 • 2012 ACR/ARHP Annual Meeting
Childhood-Onset Predicts Increased Disease Damage and Steroid Toxicity in a Cohort of Adults with Systemic Lupus Erythematosus
Erica F. Lawson¹, Laura Trupin², Jinoos Yazdany³, Aimee Hersh⁴, Emily von Scheven⁵ and Edward H. Yelin⁶, ¹Pediatrics, University of California, San Francisco, San Francisco, CA, ²Medicine, University of California San Francisco, San Francisco, CA, ³Medicine, University of California, San Francisco, San Francisco, CA, ⁴Pediatrics, University of Utah, Salt Lake City, UT, ⁵Pediatric Rheumatology, University of California San Francisco, San Francisco, CA, ⁶Arthritis Research Group, University of California, San Francisco, San Francisco, CA
Background/Purpose: While previous work has shown that adults with childhood-onset systemic lupus erythematosus (cSLE) have increased risk of mortality, renal disease and myocardial infarction as…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].